Kyverna Therapeutics (KYTX) Change in Account Payables (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Change in Account Payables data on file, last reported at $6.3 million in Q1 2026.

• Quarterly Change in Account Payables rose 65.83% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9000.0 (down 100.62% YoY) and the FY2025 annual result came in at -$2.5 million, down 439.67% from the prior year.
• Change in Account Payables improved to $6.3 million in Q1 2026, from -$892000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.3 million in Q1 2026 to a low of -$6.8 million in Q3 2025.
• A 4-year average of $661076.9 and a median of $509000.0 in 2023 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 2821.9% in 2024, down 528.78% in 2024.
• Tracing KYTX's Change in Account Payables over 4 years: stood at $3.0 million in 2023, then sank by 277.84% to -$5.3 million in 2024, then soared by 83.16% to -$892000.0 in 2025, then soared by 803.48% to $6.3 million in 2026.
• The last three Change in Account Payables figures came in at $6.3 million (Q1 2026), -$892000.0 (Q4 2025), and -$6.8 million (Q3 2025), per Business Quant data.